SCHEMBL12876360

SCHEMBL12876360

Cc1cccc(-c2nc(CCl)co2)c1F

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 3/20 0.35
ENPP1 P22413 2/20 0.35
PTPN11 Q06124 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GAA P10253 1/20 0.33
CTSA P10619 1/20 0.31
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
DRD2 P14416 2/20 0.31
DRD4 P21917 2/20 0.31
DRD3 P35462 2/20 0.31
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
HTR2A P28223 1/20 0.30
PDE4B Q07343 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487009 0.84 NPC1 (0.46) ENPP3ENPP1PTPN11NPC1RAB9A
SCHEMBL1197790 0.80 MPL (0.42) PTPN11PDE4B
SCHEMBL2227527 0.78 NOTUM (0.45) PTPN11NPC1RAB9ASMN1; SMN2GAA
SCHEMBL28331665 0.78 RAB9A (0.38) ENPP3ENPP1PTPN11NPC1RAB9A
SCHEMBL9394445 0.73 CASP3 (0.41) PTPN11NPC1RAB9AGAACASP3
SCHEMBL5015991 0.73 ALDH1A1 (0.50) PTPN11NPC1RAB9ASMN1; SMN2CASP3
SCHEMBL28331655 0.72 RAD52 (0.33) PTPN11NPC1RAB9AALDH1A1
SCHEMBL28524363 0.72 PTPN11 (0.45) PTPN11NPC1RAB9ASMN1; SMN2CASP3
SCHEMBL6965803 0.72 HDAC1 (0.50) PTPN11NPC1RAB9ASMN1; SMN2GAA
SCHEMBL28494497 0.72 NOTUM (0.49) ALDH1A1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ENPP3 1191/4885ENPP1 1304/4885PTPN11 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.